NS
NAGENDRA BOOPATHY SENGUTTUVAN
Also known as: Nagendra Boopathy, Boopathy, SN Boopathy
Sri Ramachandra Institute of Higher Education and Research, Centre for Chronic Disease Control, Icahn School of Medicine at Mount Sinai, Indian Institute of Technology
Employment
-
Sri Ramachandra Institute of Higher Education and Research Lead - Structural Heart diseases intervention2025 - Present
-
Sri Ramachandra Institute of Higher Education and Research Professor2023 - Present
-
Centre for Chronic Disease Control Head ( Honary ) Imaging2023 - Present
-
Indian Institute of Technology Adjunct Faculty2020 - 2022
-
Sri Ramachandra Institute of Higher Education and Research (Deemed to be University) Associate Professor & Senior Consultant- Interventional Cardiology2019 - 2023
-
Sri Ramachandra Institute of Higher Education adn Research Assistant Professor and Senior Consultant2017 - 2019
Education
-
Icahn School of Medicine at Mount Sinai Fellow in Structural Heart Disease Interventions2019 - 2020
-
Sri Ramachandra Institute of Higher Education and Research PhD2018 - 2025
Projects & Funding
Projects & funding information is unavailable.
Publications (78)
- Safety and performance of the Hydra self-expanding THV: 6 months outcomes from the GENESIS-II study Save
- The Standard Modifiable Cardiovascular Risk Factor Paradox Revisited Save
- Long‐Term Cardiovascular Outcomes Following Percutaneous Coronary Intervention of Diffuse Coronary Artery Lesions With Overlapping Homogeneous Versus Heterogeneous Second‐Generation Drug‐Eluting Stents Save
- Answer: Rhythmic chaos amidst brain death Save
- Clonal hematopoiesis of indeterminate potential and cardiovascular diseases: A review Save
- The silent threat: unruptured sinus of Valsalva aneurysm presenting as complete heart block Save
- Question: Rhythmic chaos amidst brain death Save
- Impact of switching antiplatelet therapy in acute coronary syndrome patients with different CYP2C19 phenotypes: insights from a single-center study. Save
- Comparing the Outcomes of Thrombus Aspiration Versus Standard Percutaneous Coronary Intervention in ST-Segment Elevation Myocardial Infarction Patients Undergoing Primary Percutaneous Coronary Intervention. Save
- Digoxin in rheumatic heart disease - Rationale and design of a multi-centre, placebo controlled double blind randomised controlled trial (Dig-RHD trial). Save